Hims & Hers appoints pharmaceutical, regulatory & quality experts to key leadership positions November 18, 2024 Company News Advocating for our customers and the care they deserve November 13, 2024 Company News How Our Technology Powers a World-Class Customer Experience ...
Find detailed information about Hims & Hers such as employee benefits and perks, company history and growth. Research how Hims & Hers compares to other Health Services company employers.
Track all pertinent news, from financial results to strategic decisions, as it happens, ensuring you never miss a beat. By knowing the backstory and the current events, you can make investment decisions rooted in comprehensive, real-time insights. Add News to Your Dashboard Take control of ...
Stay up-to-date on Hims & Hers Health, Inc. Class A Common Stock (HIMS) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com.
快讯| HIMS与HERS健康公司的股票小幅回落,成交量有所上升,《商业内幕》报道关闭皮肤科业务,股票最后上涨3.5%,报$35.60,与 session 高点$36.19相比 快讯03/08 04:37 'Hims And HERS 在FDA减肥药决定后因股票下跌而关闭了其皮肤科业务' - 业务内幕 'Hims 和 HERS 刚刚关闭了其皮肤科业务,原因是股市因FDA的减肥...
DTC健康护理品牌Hims & Hers公布2024年第二季度财报,营收达3.156亿美元,同比增长52%。 品牌方舟获悉,DTC健康护理品牌Hims& Hers公布了2024年第二季度财报。截至6月30日,Hims & Hers第二季度营收3.156亿美元,同比增长52%。 以下为Hims & Hers期内业绩概要: ...
快讯| HIMS与HERS健康公司的股票小幅回落,成交量有所上升,《商业内幕》报道关闭皮肤科业务,股票最后上涨3.5%,报$35.60,与 session 高点$36.19相比 快讯03/08 04:37 'Hims And HERS 在FDA减肥药决定后因股票下跌而关闭了其皮肤科业务' - 业务内幕 'Hims 和 HERS 刚刚关闭了其皮肤科业务,原因是股市因FDA的减肥...
品牌方舟获悉,DTC健康护理品牌Hims & Hers公布了2024年第一季度财报,收入和盈利均超出预期。以下为Hims & Hers期内业绩概要:营收为2.782亿美元,同比增长46%净收入为1110万美元,去年同期净亏损为1010万美元调整后EBITDA为3230万美元,去年同期为610万美元自由现金流为1190万美元,去年同期为700万美元Hims & Hers首席...
Related Breaking News Offers new products to support a wide range of skincare concerns. Hims & Hers Health Inc., which namedMiley Cyrus as its creative directorin 2021, has expanded both the Hims and Hers skincare collections, offering new skincare products to support a wide range of sk...
遠距醫療公司Hims and Hers Health(HIMS.US)周三公布,收購位於新澤西州的家庭實驗室測試機構 Trybe Labs,將令公司新增提供上門抽血和更全面的治療前測試服務。該股股價周三最新飆21%。 公司並未透露交易條款,但表示其透過手頭現金支付,預計將於明年推出服務。(sw/t)...